Inovio Pharmaceuticals (NASDAQ:INO) Releases Earnings Results, Misses Estimates By $0.29 EPS

Key Points

• Inovio reported a quarterly loss of $0.50 per share, missing estimates of a $0.21 loss by $0.29, while revenue of $0.30 million fell short of the $2.27 million consensus.
• The FDA granted accelerated approval to VOCERYQ, Inovio’s first commercial product, for adults with recurrent respiratory papillomatosis. The company is preparing a U.S. launch, but continued approval depends on a confirmatory study.
• Following an equity offering and warrant exercises, Inovio expects its cash to fund operations into late Q4 2027, excluding potential product revenue or additional fundraising.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share for the quarter, missing analysts' consensus estimates of ($0.21) by ($0.29), FiscalAI reports. The company had revenue of $0.30 million for the quarter, compared to analysts' expectations of $2.27 million.

Here are the key takeaways from Inovio Pharmaceuticals' conference call:

• Inovio received FDA accelerated approval for VOCERYQ, its first commercial product and the first FDA-approved plasmid DNA-based immunotherapy, for adults with recurrent respiratory papillomatosis (RRP). In the FDA’s analysis of 26 patients with at least three prior-year surgeries, 27% required no surgery in the 12 months after treatment; the company also cited durable responses and a generally favorable tolerability profile.
• Inovio is preparing a U.S. launch, with product availability expected about 60 days after approval and full field deployment targeted for Q1 2027. Management estimates at least 25,000 adult RRP patients in the U.S. and says its planned field team is designed to reach 90% of patient potential, though payer coverage and uptake estimates are based on company research.
• VOCERYQ’s accelerated approval requires a confirmatory study to verify clinical benefit, and continued approval may depend on its results. Inovio plans to submit a draft protocol by year-end and aims to agree on a final design with the FDA by mid-2027; the study is expected to include at least 50 adult and pediatric patients.
• After an equity offering that generated about $80.5 million in net proceeds, plus quarter-end cash and subsequent warrant exercises, Inovio expects to fund operations into late Q4 2027, excluding potential VOCERYQ revenue or future fundraising. The company reported Q3 operating expenses of $19.8 million, down from $21.2 million a year earlier; its $49.2 million net loss was primarily driven by a non-cash warrant fair-value adjustment.

Inovio Pharmaceuticals Stock Down 4.0%

Inovio Pharmaceuticals stock traded down $0.06 during mid-day trading on Tuesday, reaching $1.45. 14,207,659 shares of the company's stock traded hands, compared to its average volume of 4,845,135. Inovio Pharmaceuticals has a 12-month low of $0.56 and a 12-month high of $2.72. The stock has a 50 day moving average of $1.17 and a two-hundred day moving average of $1.27. The company has a market cap of $149.93 million, a price-to-earnings ratio of -1.59 and a beta of 1.71.

Analysts Set New Price Targets

Several brokerages have commented on INO. HC Wainwright set a $5.00 price target on shares of Inovio Pharmaceuticals and gave the stock a "buy" rating in a research note on Monday, November 2nd. Jefferies Financial Group reaffirmed a "buy" rating and issued a $8.00 target price (up from $3.00) on shares of Inovio Pharmaceuticals in a report on Friday. Zacks Research cut Inovio Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a report on Monday, October 12th. Wall Street Zen upgraded Inovio Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, August 15th. Finally, Weiss Ratings lowered Inovio Pharmaceuticals from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, August 13th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $5.67.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing DNA medicines, including DNA-based vaccines and immunotherapies designed to treat or prevent infectious diseases, cancers and other serious conditions. The company's platform is intended to stimulate targeted immune responses by delivering DNA medicines into cells. Inovio's product pipeline has included investigational therapies such as INO-3107, a DNA immunotherapy being developed for recurrent respiratory papillomatosis, and other candidates targeting cancer and infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.